Name | Number of supported studies | Average coverage | |
|---|---|---|---|
| fibroblast | 3 studies | 24% ± 3% | |
| oligodendrocyte | 3 studies | 20% ± 1% |
Name | Number of supported studies | Average coverage | |
|---|---|---|---|
| brain | 3 studies | 27% ± 5% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
|---|---|---|---|---|---|---|
| lung | 82% | 82.43 | 475 / 578 | 75% | 46.83 | 864 / 1155 |
| pancreas | 59% | 27.31 | 193 / 328 | 86% | 150.82 | 153 / 178 |
| breast | 55% | 23.86 | 251 / 459 | 90% | 158.00 | 1007 / 1118 |
| ovary | 89% | 118.75 | 161 / 180 | 46% | 23.59 | 196 / 430 |
| thymus | 89% | 84.48 | 581 / 653 | 20% | 7.56 | 121 / 605 |
| skin | 79% | 143.52 | 1422 / 1809 | 14% | 3.51 | 67 / 472 |
| spleen | 93% | 77.41 | 223 / 241 | 0% | 0 | 0 / 0 |
| stomach | 38% | 7.09 | 138 / 359 | 53% | 32.07 | 153 / 286 |
| blood vessel | 88% | 120.33 | 1179 / 1335 | 0% | 0 | 0 / 0 |
| prostate | 59% | 54.50 | 144 / 245 | 25% | 7.67 | 127 / 502 |
| bladder | 33% | 4.57 | 7 / 21 | 44% | 24.43 | 220 / 504 |
| intestine | 24% | 4.35 | 230 / 966 | 50% | 33.31 | 262 / 527 |
| uterus | 47% | 12.06 | 80 / 170 | 23% | 11.26 | 107 / 459 |
| esophagus | 16% | 2.98 | 235 / 1445 | 50% | 33.69 | 92 / 183 |
| kidney | 58% | 31.97 | 52 / 89 | 3% | 0.96 | 28 / 901 |
| brain | 57% | 25.23 | 1516 / 2642 | 1% | 0.23 | 6 / 705 |
| adipose | 52% | 29.25 | 627 / 1204 | 0% | 0 | 0 / 0 |
| tonsil | 0% | 0 | 0 / 0 | 40% | 22.43 | 18 / 45 |
| peripheral blood | 32% | 8.99 | 301 / 929 | 0% | 0 | 0 / 0 |
| heart | 31% | 9.98 | 271 / 861 | 0% | 0 | 0 / 0 |
| liver | 22% | 6.53 | 50 / 226 | 7% | 2.71 | 30 / 406 |
| adrenal gland | 17% | 2.91 | 44 / 258 | 0% | 0.08 | 1 / 230 |
| muscle | 7% | 2.29 | 58 / 803 | 0% | 0 | 0 / 0 |
| lymph node | 0% | 0 | 0 / 0 | 3% | 0.44 | 1 / 29 |
| abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| eye | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 80 |
| gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
| GO_0001501 | Biological process | skeletal system development |
| GO_0030198 | Biological process | extracellular matrix organization |
| GO_0005615 | Cellular component | extracellular space |
| GO_0005788 | Cellular component | endoplasmic reticulum lumen |
| GO_0005581 | Cellular component | collagen trimer |
| GO_0005576 | Cellular component | extracellular region |
| GO_0062023 | Cellular component | collagen-containing extracellular matrix |
| GO_0005599 | Cellular component | collagen type X trimer |
| GO_0030020 | Molecular function | extracellular matrix structural constituent conferring tensile strength |
| GO_0005515 | Molecular function | protein binding |
| GO_0046872 | Molecular function | metal ion binding |
| Gene name | COL10A1 |
| Protein name | Collagen alpha-1(X) chain Collagen type X alpha 1 chain |
| Synonyms | |
| Description | FUNCTION: Type X collagen is a product of hypertrophic chondrocytes and has been localized to presumptive mineralization zones of hyaline cartilage. |
| Accessions | Q5QPC7 ENST00000418500.1 ENST00000327673.4 ENST00000651968.1 ENST00000243222.8 Q03692 ENST00000452729.1 Q5QPC8 A0A650AXN9 |